Keyword: Hemlibra


9. Bayer

As Bayer completed the gigantic Monsanto crop science buyout in summer 2018, it started a large overhaul that will cut its animal health business, some consumer health brands and 10% of its workforce.

2. Roche

Roche grew sales by 7% in 2018, even as biosimilar rivals unleashed damage in Europe. But 2019 will be the moment of truth for the Swiss drugmaker. U.S. copycats to its trio of cancer megablockbusters—Herceptin, Rituxan and Avastin—are expected to arrive.